Zydus Cadila

Zydus Lifesciences Limited, commonly known as Zydus Cadila, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. Founded in 1952, the company is now publicly traded on the Bombay Stock Exchange (BSE: 532321) and the National Stock Exchange of India (NSE: ZYDUSLIFE). As of 2025, Zydus Lifesciences reported revenues in the range of $2.5 billion to $2.9 billion and employs over 25,000 people.

Zydus is a global healthcare provider primarily engaged in the manufacturing of generic drugs. The company's operations span the pharmaceutical value chain, with a product portfolio that includes active pharmaceutical ingredients (APIs), human drug formulations, vaccines, biosimilars, animal health products, and consumer wellness products. Its therapeutic areas of focus include cardiology, anti-diabetes, and specialty treatments in oncology and nephrology. The company's U.S. arm, Zydus Pharmaceuticals (USA) Inc., markets hundreds of generic products in the United States.

As a major generics manufacturer, Zydus Lifesciences is an operating company that is typically a defendant in patent litigation. The provided data, showing one case as a defendant and none as a plaintiff, is consistent with this business model. This type of litigation often arises when a company seeks regulatory approval to market a generic version of a branded drug. The single tracked case was filed in the District of Delaware, a common venue for pharmaceutical patent disputes.

The company's only tracked patent case is Veloxis Pharmaceuticals AS v. Zydus Cadila et al., filed on April 23, 2026. This lawsuit is an Abbreviated New Drug Application (ANDA) patent infringement case, where the brand-name drug company, Veloxis, is suing Zydus over its attempt to market a generic version of a drug. Both Zydus Lifesciences Ltd. and its U.S. subsidiary are named as defendants in the suit.